SHSE:688621'
s Operating Margin % Range Over the Past 10 Years
Min: 6.28 Med: 24.76 Max: 28.06
Current: 24.35
SHSE:688621's Operating Margin % is ranked better than 89.44% of 956
companies
in the Drug Manufacturers industry
Industry Median: 7.58
vs SHSE:688621: 24.35
Beijing Sun-Novo Pharmaceutical Research Co Ltd has recorded a loss in operating income at least once over the past 3 years.
Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) Operating Margin % Explanation
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Beijing Sun-Novo Pharmaceutical Research Co Operating Margin % Related Terms
Beijing Sun-Novo Pharmaceutical Research Co Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sun-Novo Pharmaceutical Research Co Operating Margin % Chart
Beijing Sun-Novo Pharmaceutical Research Co Annual Data
SHSE:688621 vs ZTS, UTHR: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Sun-Novo Pharmaceutical Research Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Sun-Novo Pharmaceutical Research Co Operating Margin % vs Drug Manufacturers Industry
Beijing Sun-Novo Pharmaceutical Research Co Operating Margin % Calculation
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) has a Operating Margin % of 6.34% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. This is 74% below median its historical median of 24.76. Over the past decade, Beijing Sun-Novo Pharmaceutical Research Co's Operating Margin % has ranged from 6.28 to 28.06. According to the industry distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #101 out of 956 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is Beijing Sun-Novo Pharmaceutical Research Co's Operating Margin % too high?
Beijing Sun-Novo Pharmaceutical Research Co's current Operating Margin % of 6.34% is 74% below median its 10-year median of 24.76. Over the past 10 years, this metric has ranged from a low of 6.28 to a high of 28.06. The Drug Manufacturers industry median Operating Margin % is 7.58. Beijing Sun-Novo Pharmaceutical Research Co's value of 6.34% is 16.4% below this industry median. Based on the distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #101 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Sun-Novo Pharmaceutical Research Co has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sun-Novo Pharmaceutical Research Co's Operating Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #101 out of 956 companies for Operating Margin %. This places Beijing Sun-Novo Pharmaceutical Research Co in the top 11% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 7.58. Beijing Sun-Novo Pharmaceutical Research Co's value of 6.34% is 16.4% below this benchmark. Historically, Beijing Sun-Novo Pharmaceutical Research Co's own Operating Margin % has ranged from 6.28 to 28.06 over the past decade. While the company's 10-year median is 24.76 vs. the industry median of 7.58, Beijing Sun-Novo Pharmaceutical Research Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.58, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Sun-Novo Pharmaceutical Research Co's current Operating Margin % of 6.34% is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Sun-Novo Pharmaceutical Research Co's current Operating Margin % is 6.34%, which is 74% below median its own 10-year median of 24.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sun-Novo Pharmaceutical Research Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥69.90, compared to a current price of ¥49.10 — trading 29.8% below its estimated fair value. The current Operating Margin % is 6.34%, which is 74% below median its 10-year median of 24.76 and 16.4% below the Drug Manufacturers industry median of 7.58. Beijing Sun-Novo Pharmaceutical Research Co's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621), the current Operating Margin % is 6.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co stock appears to be undervalued.
The current stock price of ¥49.10 is trading 29.8% below its estimated GF Value™ of ¥69.90.
GuruFocus considers Beijing Sun-Novo Pharmaceutical Research Co to be Significantly Undervalued.
Key valuation signals for SHSE:688621:
Operating Margin %: 6.34% (74% below median its 10-year median of 24.76)
GF Value™: ¥69.90 vs. price of ¥49.10 (29.8% below fair value)
Industry Position: 16.4% below the Drug Manufacturers median (#101 of 956)
No single metric tells the full story. See the SHSE:688621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Sun-Novo Pharmaceutical Research Co Business Description
Beijing Sun-Novo Pharmaceutical Research Co Ltd is engaged in providing professional research and development outsourcing services for pharmaceutical companies.
85GF Score
Get the complete analysis for SHSE:688621
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688621 has been successfully added to your 
